Characterization of thrombin receptor expression during vascular lesion formation.
Blood vessels respond to injury by initiating cell proliferation and migration that result in vascular lesion formation. To determine the roles of thrombin and the thrombin receptor in this process, we characterized thrombin receptor expression in normal and injured arteries, thrombin receptor-mediated smooth muscle cell mitogenesis, and the regulation of thrombin receptor mRNA expression in vitro. Thrombin receptor mRNA was not detected in normal rat or baboon arteries by in situ hybridization. Immunohistochemistry using an antithrombin receptor antibody (TR-R9), directed against the thrombin cleavage site of the rat aortic smooth muscle cell thrombin receptor, revealed low-level staining for thrombin receptor protein in endothelial cells and smooth muscle cells of normal arteries. In contrast, balloon catheter injury increased thrombin mRNA expression in medial smooth muscle cells within 6 hours. This increased thrombin receptor expression continued within the media and in neointimal cells throughout vascular lesion formation, predominantly in areas of active cell proliferation. In vitro, alpha-thrombin stimulates rat aortic smooth muscle cell proliferation in a concentration-dependent manner. That thrombin receptor activation is required for the mitogenic response was confirmed by demonstrating that the polyclonal antibody TR-R9 inhibits thrombin-induced cell proliferation. Thrombin receptor mRNA synthesis was induced by both basic fibroblast growth factor (maximal stimulation of 1.8-fold at 1 hour) and platelet-derived growth factor (maximal stimulation of 2.4-fold at 8 and 24 hours) in quiesced cultured rat aortic smooth muscle cells. In summary, upregulation of smooth muscle cell thrombin receptor expression occurs very early after vascular injury and continues throughout neointimal development.(ABSTRACT TRUNCATED AT 250 WORDS)
Wilcox
J N
JN
Division of Hematology/Oncology, Emory University, Atlanta, Ga.
Rodriguez
J
J
Subramanian
R
R
Ollerenshaw
J
J
Zhong
C
C
Hayzer
D J
DJ
Horaist
C
C
Hanson
S R
SR
Lumsden
A
A
Salam
T A
TA
D017130:Angioplasty; D000818:Animals; D000918:Antibody Specificity; D001161:Arteriosclerosis / Q000473:pathology*; D001808:Blood Vessels / Q000293:injuries*; D015152:Blotting, Northern; D002478:Cells, Cultured; D004691:Endarterectomy; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D009131:Muscle, Smooth, Vascular / Q000293:injuries / Q000473:pathology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D018179:Receptors, Thrombin / Q000187:drug effects / Q000235:genetics* / Q000276:immunology; D013917:Thrombin / Q000302:isolation & purification; D015854:Up-Regulation
D010982:Platelet-Derived Growth Factor; D012333:RNA, Messenger; D018179:Receptors, Thrombin; D016222:Fibroblast Growth Factor 2; D013917:Thrombin